<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2022-3103</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-3103</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>COVID-19 И БОЛЕЗНИ СИСТЕМЫ КРОВООБРАЩЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COVID-19 AND DISEASES OF THE CIRCULATORY SYSTEM</subject></subj-group></article-categories><title-group><article-title>Шкалы NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick как инструменты оценки исходов тяжелой формы COVID-19 (пилотное ретроспективное когортное исследование)</article-title><trans-title-group xml:lang="en"><trans-title>NEWS2, 4C Mortality Score, COVID-GRAM, Sequential Organ Failure Assessment Quick scales as outcomes assessment tools for severe COVID-19 (pilot retrospective cohort study)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3568-5065</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Вечорко</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vechorko</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Вечорко Валерий Иванович  — кандидат медицинских наук, доцент, главный врач</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">emma.makoeva123@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3010-755X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Аверков</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Averkov</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Аверков Олег Валерьевич  — доктор медицинских наук, профессор, заместитель главного врача по лечебной работе</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">oleg.averkov@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3810-9971</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гришин</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Grishin</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гришин Дмитрий Валерьевич — врач-невролог</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">tulip270@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9226-2870</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зимин</surname><given-names>А. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zimin</surname><given-names>A. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Зимин Алексей Алексеевич — кандидат педагогических наук, аналитик, научный сотрудник</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">leha-zimin@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ “ГКБ № 15 им. О.М. Филатова” Департамента здравоохранения города Москвы</institution></aff><aff xml:lang="en"><institution>O.M. Filatov City Clinical Hospital № 15</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ “ГКБ № 15 им. О.М. Филатова” Департамента здравоохранения города Москвы;&#13;
ФГБНУ “Научный центр неврологии”</institution></aff><aff xml:lang="en"><institution>O.M. Filatov City Clinical Hospital № 15;&#13;
Research Center of Neurology</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>26</day><month>01</month><year>2022</year></pub-date><volume>21</volume><issue>3</issue><fpage>3103</fpage><lpage>3103</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Вечорко В.И., Аверков О.В., Гришин Д.В., Зимин А.А., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Вечорко В.И., Аверков О.В., Гришин Д.В., Зимин А.А.</copyright-holder><copyright-holder xml:lang="en">Vechorko V.I., Averkov O.V., Grishin D.V., Zimin A.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/3103">https://cardiovascular.elpub.ru/jour/article/view/3103</self-uri><abstract><sec><title>Цель</title><p>Цель. Исследовать прогностическую способность шкал NEWS2, 4C Mortality Score, COVID-GRAM и  qSOFA в  предсказании клинических исходов у пациентов с тяжелой формой COVID-19 (COrona VIrus Disease 2019), госпитализированных в многопрофильный стационар.</p></sec><sec><title>Материал и  методы</title><p>Материал и  методы. В  пилотном ретроспективном когортном исследовании использованы данные 90 больных (52 пациента  — подгруппа отделения реанимации и  интенсивной терапии, 38 пациентов  — подгруппа коечного отделения) с  подтвержденным диагнозом COVID-19, госпитализированных в  ГКБ № 15 им. О.М. Филатова (г. Москва) в период с января по март 2021г.</p></sec><sec><title>Результаты</title><p>Результаты. Вероятность положительного исхода заболевания, значимо отрицательно коррелирует с  возрастом пациента (R=-0,514; р=0,0002). Наилучшую корреляцию с исходом COVID-19 имеет оценка по шкале 4С Mortality Score (R=0,836; р=0,0001). Логистический регрессионный анализ выявил значимую зависимость параметров “исход” и “возраст” с наибольшей точностью в виде возрастных подгрупп по классификации Всемирной организации здравоохранения с  отношением шансов (ОШ)=4,29 (р=0,0001). В  результате ROCанализа лучшая предсказательная способность исходов заболевания показана для шкал 4С Mortality Score (AUC — area under curve (площадь под кривой)=0,878; 95% доверительный интервал (ДИ): 0,782- 0,975 (p=0,00001) и  COVID-GRAM (AUC=0,807; 95% ДИ: 0,720-0,895 (p=0,00001); с учетом разделения пациентов на возрастные подгруппы получены оптимальные предиктивные инструменты: в  подгруппах 18-44 лет и 45-59 лет — шкала 4С Mortality Score — AUC=0,892, 95% ДИ: 0,762-0,980 (р=0,002) и  AUC=0,853, 95% ДИ: 0,784-0,961 (р=0,0014), соответственно; в подгруппе 60-74 лет — шкала COVIDGRAM  — AUC=0,833, 95% ДИ: 0,682-0,990 (р=0,038); в  подгруппах 75-90 лет и &gt;90 лет — шкала NEWS2 — AUC=0,958, 95% ДИ: 0,807-1,0 (р=0,002) и AUC=0,818, 95% ДИ: 0,713-0,996 (р=0,006), соответственно. Совместное использование шкал 4С Mortality Score и  COVIDGRAM снижало их прогностическую ценность — AUC=0,784, 95% ДИ: 0,689-0,814 (р=0,008). С  помощью ROC-анализа показано, что возраст 70 лет является пороговым значением, при превышении которого значимо увеличивается вероятность неблагоприятного исхода COVID-19: ОШ=11,63; 95% ДИ: 9,72-12,06 (р=0,0052).</p></sec><sec><title>Заключение</title><p>Заключение. Результаты пилотного исследования показали достоверность прогнозирования исхода госпитализации пациентов с  тяжелой формой COVID-19. Наилучшей предсказательной точностью обладали шкалы 4С Mortality Score и  COVID-GRAM. Специфичность и чувствительность оценок по шкалам зависела от возраста пациента. Возраст 70 лет являлся пороговым значением, при достижении которого риск неблагоприятного исхода значимо увеличивался. На основе данных проведенного пилотного исследования запланировано изучение проблемы прогнозирования течения заболевания с учетом степени тяжести COVID-19.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the predictive ability of the NEWS2, 4C Mortality Score, COVID-GRAM and qSOFA scales in predicting clinical outcomes in patients with severe coronavirus disease 2019 (COVID-19) hospitalized in a multidisciplinary hospital.</p></sec><sec><title>Material and methods</title><p>Material and methods. The pilot retrospective cohort study used data from 90 patients (52 — intensive care unit subgroup, 38 — general unit subgroup) with a confirmed diagnosis of COVID-19 hospitalized in the O.M. Filatov City Clinical Hospital № 15 (Moscow) from January to March 2021.</p></sec><sec><title>Results</title><p>Results. The probability of a positive outcome of the disease significantly negatively correlates with the patient’s age (R=-0,514; p=0,0002). The best correlation with the COVID-19 outcome had a 4C Mortality Score (R=0,836; p=0,0001). Logistic regression revealed a significant dependence of the “outcome” and “age” parameters with the greatest accuracy in the form of age subgroups according to the World Health Organization classification with odds ratio (OR) of 4,29 (p=0,0001). As a result of ROC analysis, the best predictive ability of disease outcomes was shown for the 4C Mortality Score (area under curve (AUC)=0,878; 95% confidence interval (CI): 0,782- 0,975 (p=0,00001)) and COVID-GRAM (AUC=0,807; 95% CI: 0,720- 0,895 (p=0,00001)); taking into account the division of patients into age subgroups, optimal predictive tools were obtained: in subgroups 18-44 years old and 45-59 years old  — the 4С Mortality Score (AUC=0,892, 95% CI: 0,762-0,980 (p=0,002) and AUC=0,853, 95% CI: 0,784-0,961 (p=0,0014), respectively); in the subgroup 60-74 years old — the COVID-GRAM (AUC=0,833, 95% CI: 0,682-0,990 (p=0,038)); in subgroups 75-90 years and &gt;90 years  — NEWS2 (AUC=0,958, 95% CI: 0,807-1,0 (p=0,002) and AUC=0,818, 95% CI: 0,713-0,996 (p=0,006), respectively). ROC analysis showed that the age of 70 years is the threshold value, above which the probability of an unfavorable COVID-19 outcome increases significantly (OR=11,63; 95% CI: 9,72- 12,06 (p=0,0052)).</p></sec><sec><title>Conclusion</title><p>Conclusion. The pilot study showed the significance of predicting the hospitalization outcome of patients with severe COVID-19. The 4C Mortality Score and COVID-GRAM scales had the best predictive accuracy. The specificity and sensitivity of the scores depended on the age of a patient. The age of 70 years was the threshold value at which the risk of an adverse outcome increased significantly. Based on the data obtained, it is planned to study the problem of predicting the disease course, taking into account the severity of COVID-19.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>шкалы</kwd><kwd>прогнозирование</kwd><kwd>чувствительность</kwd><kwd>специфичность</kwd><kwd>исходы заболевания</kwd><kwd>ROC-анализ регрессионный анализ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>scales</kwd><kwd>prediction</kwd><kwd>sensitivity</kwd><kwd>specificity</kwd><kwd>disease outcomes</kwd><kwd>ROC analysis</kwd><kwd>regression analysis</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 Coronavirus pandemic. http://www.worldometers.info/coronavirus (16 January 2022).</mixed-citation><mixed-citation xml:lang="en">COVID-19 Coronavirus pandemic. http://www.worldometers.info/coronavirus (16 January 2022).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Coronavirus disease 2019 (COVID-19) Situation Report–46. http://www.who.int/emergencies/diseases/novel-coronavirus-2019 (26 October 2021).</mixed-citation><mixed-citation xml:lang="en">Coronavirus disease 2019 (COVID-19) Situation Report–46. http://www.who.int/emergencies/diseases/novel-coronavirus-2019 (26 October 2021).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.</mixed-citation><mixed-citation xml:lang="en">Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Беграмбекова Ю. Л., Мареев Ю. В. Как оценивать результаты лечения больных с новой коронавирусной инфекцией (COVID-19)? Шкала Оценки Клинического Состояния (ШОКС-КОВИД). Кардиология. 2020;11:35-41. doi:10.18087/cardio.2020.11.n1439.</mixed-citation><mixed-citation xml:lang="en">Мареев В.Ю., Беграмбекова Ю. Л., Мареев Ю. В. Как оценивать результаты лечения больных с новой коронавирусной инфекцией (COVID-19)? Шкала Оценки Клинического Состояния (ШОКС-КОВИД). Кардиология. 2020;11:35-41. doi:10.18087/cardio.2020.11.n1439.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Scale for assessing the severity of the condition for patients with COVID-19. (In Russ.) Шкала оценки тяжести состояния для пациентов с COVID-19. http://www.1spbgmu.ru/ru/klinika/shkalaotsenki-tyazhesti-sostoyaniya-dlya-patsientov-s-covid-19 (12 October 2021).</mixed-citation><mixed-citation xml:lang="en">Scale for assessing the severity of the condition for patients with COVID-19. (In Russ.) Шкала оценки тяжести состояния для пациентов с COVID-19. http://www.1spbgmu.ru/ru/klinika/shkalaotsenki-tyazhesti-sostoyaniya-dlya-patsientov-s-covid-19 (12 October 2021).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. http://www.covid19treatmentguidelines.nih.gov (12 October 2021).</mixed-citation><mixed-citation xml:lang="en">COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. http://www.covid19treatmentguidelines.nih.gov (12 October 2021).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Greenhalgh T, Treadwell J, Burrow R, et al. Should we use the NEWS (or NEWS2) score when assessing patients with possible COVID-19 in primary care? Project: COVID-19 Infection Prevention and Control. 2020. doi:10.13140/RG.2.2.26433.10089. https://www.researchgate.net/publication/340934244_Should_we_use_the_NEWS_or_NEWS2_score_when_assessing_patients_with_possible_COVID-19_in_primary_care. (10 October 2021).</mixed-citation><mixed-citation xml:lang="en">Greenhalgh T, Treadwell J, Burrow R, et al. Should we use the NEWS (or NEWS2) score when assessing patients with possible COVID-19 in primary care? Project: COVID-19 Infection Prevention and Control. 2020. doi:10.13140/RG.2.2.26433.10089. https://www.researchgate.net/publication/340934244_Should_we_use_the_NEWS_or_NEWS2_score_when_assessing_patients_with_possible_COVID-19_in_primary_care. (10 October 2021).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Benjamin GM, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021;31:1-10. doi:10.1002/rmv.2146.</mixed-citation><mixed-citation xml:lang="en">Benjamin GM, Aghagoli G, Lavine K, et al. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021;31:1-10. doi:10.1002/rmv.2146.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Временные методические рекомендации “Про - филактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)”. Версия 13 (14.10.2021). https://edu.rosminzdrav.ru/index.php?id=250 (16 октября 2021).</mixed-citation><mixed-citation xml:lang="en">Interim Guidelines for Prevention, Diagnosis and Treatment of Novel Coronavirus Infection (COVID-19). Version 13 (14.10.2021). (In Russ.) https://edu.rosminzdrav.ru/index.php?id=250 (16 October 2021).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">D’Arrigo G, Roumeliotis S, Torino C, et al. Sample size calculation of clinical trials in geriatric medicine. Aging Clin Exp Res. 2021;33:1209-12. doi:10.1007/s40520-020-01595-z.</mixed-citation><mixed-citation xml:lang="en">D’Arrigo G, Roumeliotis S, Torino C, et al. Sample size calculation of clinical trials in geriatric medicine. Aging Clin Exp Res. 2021;33:1209-12. doi:10.1007/s40520-020-01595-z.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Martín-Rodríguez F, López-Izquierdo R, Del Pozo Vegas C, et al. Can the prehospital National Early Warning Score 2 identify patients at risk of in-hospital early mortality? A prospective, multicenter cohort study. Heart Lung. 2020;49:585-91. doi:10.1016/j.hrtlng.2020.02.047.</mixed-citation><mixed-citation xml:lang="en">Martín-Rodríguez F, López-Izquierdo R, Del Pozo Vegas C, et al. Can the prehospital National Early Warning Score 2 identify patients at risk of in-hospital early mortality? A prospective, multicenter cohort study. Heart Lung. 2020;49:585-91. doi:10.1016/j.hrtlng.2020.02.047.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Cecconi M, Piovani D, Brunetta E, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy. J Clin Med. 2020;9:1548. doi:10.3390/jcm9051548.</mixed-citation><mixed-citation xml:lang="en">Cecconi M, Piovani D, Brunetta E, et al. Early predictors of clinical deterioration in a cohort of 239 patients hospitalized for Covid-19 infection in Lombardy, Italy. J Clin Med. 2020;9:1548. doi:10.3390/jcm9051548.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hernández-Garduño E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. Obes Res Clin Pract. 2020;14:375-9. doi:10.1016/j.orcp.2020.06.001.</mixed-citation><mixed-citation xml:lang="en">Hernández-Garduño E. Obesity is the comorbidity more strongly associated for Covid-19 in Mexico. A case-control study. Obes Res Clin Pract. 2020;14:375-9. doi:10.1016/j.orcp.2020.06.001.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Int Med. 2020;288:469-76. doi:10.1111/joim.13119.</mixed-citation><mixed-citation xml:lang="en">Imam Z, Odish F, Gill I, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Int Med. 2020;288:469-76. doi:10.1111/joim.13119.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020;146:110-8. doi:10.1016/j.jaci.2020.04.006.</mixed-citation><mixed-citation xml:lang="en">Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 in patients in Wuhan. J Allergy Clin Immunol. 2020;146:110-8. doi:10.1016/j.jaci.2020.04.006.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
